JPM26 Day 3: Sanofi CEO on RSV Scrutiny and Regeneron Dupixent Defense
Sanofi CEO Paul Hudson discussed FDA scrutiny of Beyfortus, their RSV prophylactic antibody, amid broader vaccine policy changes and risk-benefit questions at JPM26126.
Sanofi defends Beyfortus with randomized trial data and real-world studies showing reduced hospitalizations and ancillary benefits, as stated by R&D chief Houman Ashrafian2.
Hudson noted Beyfortus's half-life covers the full RSV season, contrasting with competitors like Merck6.
Sanofi faces FDA rejection of tolebrutinib for MS due to liver toxicity concerns, but Hudson highlighted its efficacy and patient willingness to monitor liver for 90 days2.
The query mentions Regeneron defending Dupixent strategy, but search results focus primarily on Sanofi's presentations; no direct Day 3 details on Regeneron found in provided sources125.
Sanofi executives, including CEO Paul Hudson, CFO François Roger, and R&D head Houman Ashrafian, presented on January 12, 2026, at the conference15.
Sources:
1. https://www.gurufocus.com/news/4107403/sanofi-sa-at-jpmorgan-healthcare-conference-transcript
2. https://www.fiercebiotech.com/biotech/jpm26-after-important-year-sanofi-looks-ahead-remaining-federal-challenges
5. https://www.sanofi.com/en/investors/broker-conferences/44th-annual-jp-morgan-healthcare